围手术期系统治疗对比单纯CRS-HIPEC治疗可切除结直肠腹膜转移:2期随机临床试验
该2期随机试验在荷兰9个中心纳入79例可切除结直肠腹膜转移患者,比较围手术期系统治疗与单纯CRS-HIPEC。两组宏观完全CRS-HIPEC比例和Clavien-Dindo≥3级术后并发症无显著差异,新辅助治疗客观影像学缓解率28%、主要病理缓解率38%,围手术期系统治疗可行、安全且能诱导缓解。
要点
- 围手术期系统治疗未显著影响宏观完全CRS-HIPEC比例(89% vs 86%)。
- 围手术期系统治疗未显著增加Clavien-Dindo≥3级术后并发症(22% vs 33%)。
- 新辅助治疗客观影像学缓解率28%,主要病理缓解率38%。
核心结论
- 在可切除结直肠腹膜转移患者中,围手术期系统治疗看似可行、安全,并能诱导腹膜转移灶缓解,支持开展3期试验。
研究设计与样本
- 开放标签、平行分组2期随机临床试验,在荷兰全部9个三级中心开展,2017年6月15日至2019年1月9日纳入79例经病理证实的孤立可切除结直肠腹膜转移患者。
- 纳入分析79例(43例男性,占54%;平均年龄62岁,SD 10岁),实验组37例、对照组42例。
- 分析采用改良意向性治疗,实验组为开始新辅助治疗的患者,对照组为直接手术的患者。
主要发现
- 无治疗相关死亡。
- 新辅助治疗对结直肠腹膜转移的客观影像学缓解率为28%(9/32例可评估患者),主要病理缓解率为38%(13/34例可评估患者)。
临床怎么用
- 围手术期系统治疗可作为可切除结直肠腹膜转移患者的可行选择,未增加宏观完全CRS-HIPEC比例或术后严重并发症风险。
- 新辅助系统治疗可诱导部分患者影像学和病理缓解,但需在3期试验进一步验证生存获益。
局限性
- 本研究为2期随机试验,样本量较小(79例),主要评估可行性和安全性,不足以评价生存终点。
- 新辅助缓解率基于可评估患者亚组,存在缺失数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To date, no randomized clinical trials have investigated perioperative systemic therapy relative to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) alone for resectable colorectal peritoneal metastases (CPM). OBJECTIVE: To assess the feasibility and safety of perioperative systemic therapy in patients with resectable CPM and the response of CPM to neoadjuvant treatment. DESIGN, SETTING, AND PARTICIPANTS: An open-label, parallel-group phase 2 randomized clinical trial in all 9 Dutch tertiary centers for the surgical treatment of CPM enrolled participants between June 15, 2017, and January 9, 2019. Participants were patients with pathologically proven isolated resectable CPM who did not receive systemic therapy within 6 months before enrollment. INTERVENTIONS: Randomization to perioperative systemic therapy or CRS-HIPEC alone. Perioperative systemic therapy comprised either four 3-week neoadjuvant and adjuvant cycles of CAPOX (capecitabine and oxaliplatin), six 2-week neoadjuvant and adjuvant cycles of FOLFOX (fluorouracil, leucovorin, and oxaliplatin), or six 2-week neoadjuvant cycles of FOLFIRI (fluorouracil, leucovorin, and irinotecan) and either four 3-week adjuvant cycles of capecitabine or six 2-week adjuvant cycles of fluorouracil with leucovorin. Bevacizumab was added to the first 3 (CAPOX) or 4 (FOLFOX/FOLFIRI) neoadjuvant cycles. MAIN OUTCOMES AND MEASURES: Proportions of macroscopic complete CRS-HIPEC and Clavien-Dindo grade 3 or higher postoperative morbidity. Key secondary outcomes were centrally assessed rates of objective radiologic and major pathologic response of CPM to neoadjuvant treatment. Analyses were done modified intention-to-treat in patients starting neoadjuvant treatment (experimental arm) or undergoing upfront surgery (control arm). RESULTS: In 79 patients included in the analysis (43 [54%] men; mean [SD] age, 62 [10] years), experimental (n = 37) and control (n = 42) arms did not differ significantly regarding the proportions of macroscopic complete CRS-HIPEC (33 of 37 [89%] vs 36 of 42 [86%] patients; risk ratio, 1.04; 95% CI, 0.88-1.23; P = .74) and Clavien-Dindo grade 3 or higher postoperative morbidity (8 of 37 [22%] vs 14 of 42 [33%] patients; risk ratio, 0.65; 95% CI, 0.31-1.37; P = .25). No treatment-related deaths occurred. Objective radiologic and major pathologic response rates of CPM to neoadjuvant treatment were 28% (9 of 32 evaluable patients) and 38% (13 of 34 evaluable patients), respectively. CONCLUSIONS AND RELEVANCE: In this randomized phase 2 trial in patients diagnosed with resectable CPM, perioperative systemic therapy seemed feasible, safe, and able to induce response of CPM, justifying a phase 3 trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02758951.
引用
- Rovers KP, Bakkers C, Nienhuijs SW, et al. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial. JAMA Surg. 2021. PMID: 34009291. doi:10.1001/jamasurg.2021.1642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。